Anti-tumor activity of resveratrol against gastric cancer: a review of recent advances with an emphasis on molecular pathways.
Milad AshrafizadehHossein RafieiReza MohammadinejadTahereh FarkhondehSaeed SamarghandianPublished in: Cancer cell international (2021)
Gastric cancer (GC) is one of the most common cancers with high malignancy. In spite of the great development in diagnostic tools and application of anti-tumor drugs, we have not witnessed a significant increase in the survival time of patients with GC. Multiple studies have revealed that Wnt, Nrf2, MAPK, and PI3K/Akt signaling pathways are involved in GC invasion. Besides, long non-coding RNAs and microRNAs function as upstream mediators in GC malignancy. GC cells have acquired resistance to currently applied anti-tumor drugs. Besides, combination therapy is associated with higher anti-tumor activity. Resveratrol (Res) is a non-flavonoid polyphenol with high anti-tumor activity used in treatment of various cancers. A number of studies have demonstrated the potential of Res in regulation of molecular pathways involved in cancer malignancy. At the present review, we show that Res targets a variety of signaling pathways to induce apoptotic cell death and simultaneously, to inhibit the migration and metastasis of GC cells.
Keyphrases
- cell cycle arrest
- pi k akt
- signaling pathway
- cell death
- induced apoptosis
- combination therapy
- cell proliferation
- gas chromatography
- long non coding rna
- oxidative stress
- stem cells
- epithelial mesenchymal transition
- poor prognosis
- squamous cell carcinoma
- single cell
- case control
- cell migration
- risk assessment
- anti inflammatory